{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:09:28Z","timestamp":1791472168877,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004388","name":"Oncolytics Biotech","doi-asserted-by":"publisher","award":["RM-MMC 001"],"award-info":[{"award-number":["RM-MMC 001"]}],"id":[{"id":"10.13039\/501100004388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002418","name":"Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences and Peking Union Medical College","doi-asserted-by":"crossref","award":["MMC446"],"award-info":[{"award-number":["MMC446"]}],"id":[{"id":"10.13039\/501100002418","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007319","name":"Albert Einstein College of Medicine, Yeshiva University","doi-asserted-by":"publisher","award":["2A4108"],"award-info":[{"award-number":["2A4108"]}],"id":[{"id":"10.13039\/100007319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>KRAS<\/jats:italic>\n                      mutations are prevalent in 40\u201345% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination with chemotherapy is examined in a phase 1 study of metastatic CRC. This study evaluates the nature of immune response by determining the cytokine expression pattern in peripheral circulation along with the distribution of antigen presenting cells (APCs) and activated T lymphocytes. Further the study evaluates the alterations in exosomal and cellular microRNA levels along with the effect of reovirus on leukocyte transcriptome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Reovirus was administered as a 60-min intravenous infusion for 5 consecutive days every 28\u2009days, at a tissue culture infective dose (TCID\n                      <jats:sub>50<\/jats:sub>\n                      ) of 3\u2009\u00d7\u200910\n                      <jats:sup>10<\/jats:sup>\n                      . Peripheral blood mononuclear cells (PBMC) were isolated from whole blood prior to reovirus administration and post-reovirus on days 2, 8, and 15. The expression profile of 25 cytokines in plasma was assessed (post PBMC isolation) on an EMD Millipore multiplex Luminex platform. Exosome and cellular levels of miR-29a-3p was determined in pre and post reovirus treated samples. Peripheral blood mononuclear cells were stained with fluorophore labelled antibodies against CD4, CD8, CD56, CD70, and CD123, fixed and evaluated by flow cytometry. The expression of granzyme B was determined on core biopsy of one patient. Finally, Clariom D Assay was used to determine the expression of 847 immune-related genes when compared to pre reovirus treatment by RNA sequencing analysis. A change was considered if the expression level either doubled or halved and the significance was determined at a\n                      <jats:italic>p<\/jats:italic>\n                      value of 0.001.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cytokine assay indicated upregulation at day 8 for IL-12p40 (2.95;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05); day 15 for GM-CSF (3.56;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009), IFN-y (1.86;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0004) and IL-12p70 (2.42;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). An overall reduction in IL-8, VEGF and RANTES\/CCL5 was observed over the 15-day period. Statistically significant reductions were observed at Day 15 for IL-8 (0.457-fold, 53.3% reduction;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and RANTES\/CC5 (0.524-fold, 47.6% reduction;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). An overall increase in IL-6 was observed, with statistical significance at day 8 (1.98- fold; 98% increase,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00007). APCs were stimulated within 48\u2009h and activated (CD8\n                      <jats:sup>+<\/jats:sup>\n                      CD70\n                      <jats:sup>+<\/jats:sup>\n                      ) T cells within 168\u2009h as determine by flow cytometry. Sustained reductions in exosomal and cellular levels of miR-29a-3p (a microRNA upregulated in CRC and associated with decreased expression of the tumor suppressor\n                      <jats:italic>WWOX<\/jats:italic>\n                      gene) was documented. Reovirus administration further resulted in increases in\n                      <jats:italic>KRAS<\/jats:italic>\n                      (33x)\n                      <jats:italic>, IFNAR1<\/jats:italic>\n                      (20x),\n                      <jats:italic>STAT3<\/jats:italic>\n                      (5x), and\n                      <jats:italic>TAP1<\/jats:italic>\n                      (4x) genes after 2\u2009days;\n                      <jats:italic>FGCR2A<\/jats:italic>\n                      (23x) and\n                      <jats:italic>CD244<\/jats:italic>\n                      (3x) after 8\u2009days;\n                      <jats:italic>KLRD1<\/jats:italic>\n                      (14x),\n                      <jats:italic>TAP1<\/jats:italic>\n                      (2x) and\n                      <jats:italic>CD244<\/jats:italic>\n                      (2x) after 15\u2009days. Reductions (&gt;\u20090.5x) were observed in\n                      <jats:italic>VEGFA<\/jats:italic>\n                      (2x) after 2\u2009days\n                      <jats:italic>; CXCR2<\/jats:italic>\n                      (2x),\n                      <jats:italic>ITGAM<\/jats:italic>\n                      (3x) after 15\u2009days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reovirus has profound immunomodulatory properties that span the genomic, protein and immune cell distribution levels. This is the first study with reovirus in cancer patients that demonstrates these multi- layered effects, demonstrating how reovirus can function as an immune stimulant (augmenting the efficacy of immuno-chemo-therapeutic drugs), and an oncolytic agent. Reovirus thus functions bimodally as an oncolytic agent causing lysis of tumor cells, and facilitator of immune-mediated recognition and destruction of tumor cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07038-2","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T04:02:47Z","timestamp":1592452967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Immune characterization of metastatic colorectal cancer patients post reovirus administration"],"prefix":"10.1186","volume":"20","author":[{"given":"Ruwan","family":"Parakrama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Chandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titto","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Tesfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5365-5890","authenticated-orcid":false,"given":"Radhashree","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"issue":"1","key":"7038_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"key":"7038_CR2","volume-title":"Survival rates for colorectal cancer","author":"American Cancer Society","year":"2020","unstructured":"American Cancer Society. Survival rates for colorectal cancer. 2020. https:\/\/www.cancer.org\/cancer\/colon-rectal-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"7038_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9450754","volume":"2018","author":"IS Yu","year":"2018","unstructured":"Yu IS, Cheung WY. Metastatic colorectal cancer in the era of personalized medicine: a more tailored approach to systemic therapy. Can J Gastroenterol Hepatol. 2018;2018:1\u201311. https:\/\/doi.org\/10.1155\/2018\/9450754.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"January","key":"7038_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2018.07.001","volume":"130","author":"A Stein","year":"2018","unstructured":"Stein A, Markus M, J\u00f6rg T, Eray G, Vogel A. Immuno-oncology in GI tumours: clinical evidence and emerging trials of PD-1\/PD-L1 antagonists. Crit Rev Oncol Hematol. 2018;130(January):13\u201326. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.07.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"7038_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","volume":"7","author":"CJ LaRocca","year":"2018","unstructured":"LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7(1):35. https:\/\/doi.org\/10.1186\/s40169-018-0214-5.","journal-title":"Clin Transl Med"},{"issue":"10","key":"7038_CR6","doi-asserted-by":"publisher","first-page":"12153","DOI":"10.3390\/ijms131012153","volume":"13","author":"AK Arrington","year":"2012","unstructured":"Arrington AK, Heinrich EL, Lee W, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13(10):12153\u201368. https:\/\/doi.org\/10.3390\/ijms131012153.","journal-title":"Int J Mol Sci"},{"issue":"5392","key":"7038_CR7","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","volume":"282","author":"MC Coffey","year":"1998","unstructured":"Coffey MC, Strong JE, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated Ras pathway. Science (80- ). 1998;282(5392):1332.","journal-title":"Science (80- )"},{"issue":"2","key":"7038_CR8","first-page":"348","volume":"63","author":"K Hirasawa","year":"2003","unstructured":"Hirasawa K, Nishikawa SG, Norman KL, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res. 2003;63(2):348\u201353.","journal-title":"Cancer Res"},{"issue":"6","key":"7038_CR9","first-page":"1696","volume":"62","author":"K Hirasawa","year":"2002","unstructured":"Hirasawa K, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 2002;62(6):1696\u2013701.","journal-title":"Cancer Res"},{"issue":"9","key":"7038_CR10","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.18632\/oncotarget.1921","volume":"5","author":"R Maitra","year":"2014","unstructured":"Maitra R, Seetharam R, Tesfa L, et al. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget. 2014;5(9):2807\u201319. https:\/\/doi.org\/10.18632\/oncotarget.1921.","journal-title":"Oncotarget"},{"key":"7038_CR11","doi-asserted-by":"publisher","unstructured":"Goel S, Ocean AJ, Parakrama RY, et al. Elucidation of reovirus pharmacodynamics in A phase I trial in patients with Kras mutated colorectal cancer. Mol Cancer Ther. 2020. https:\/\/doi.org\/10.1158\/1535-7163.mct-19-1117.","DOI":"10.1158\/1535-7163.mct-19-1117"},{"issue":"6","key":"7038_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","volume":"50","author":"SW Kim","year":"2016","unstructured":"Kim SW, Roh J, Park CS. Immunohistochemistry for pathologists: protocols, pitfalls, and tips. J Pathol Transl Med. 2016;50(6):411\u20138. https:\/\/doi.org\/10.4132\/jptm.2016.08.08.","journal-title":"J Pathol Transl Med"},{"issue":"4","key":"7038_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods. 2001;25(4):402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262.","journal-title":"Methods"},{"issue":"APR","key":"7038_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00171","volume":"5","author":"SR Huber","year":"2014","unstructured":"Huber SR, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections - opportunities for peptide vaccination. Front Immunol. 2014;5(APR):1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2014.00171.","journal-title":"Front Immunol"},{"issue":"September 2018","key":"7038_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.biopha.2018.11.105","volume":"110","author":"N Yaghoubi","year":"2019","unstructured":"Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1\/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110(September 2018):312\u20138. https:\/\/doi.org\/10.1016\/j.biopha.2018.11.105.","journal-title":"Biomed Pharmacother"},{"issue":"16","key":"7038_CR16","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-12-1337","volume":"72","author":"MWL Teng","year":"2012","unstructured":"Teng MWL, Vesely MD, Duret H, et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res. 2012;72(16):3987\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1337.","journal-title":"Cancer Res"},{"issue":"1","key":"7038_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.gene.2015.04.065","volume":"567","author":"M Kara","year":"2015","unstructured":"Kara M, Yumrutas O, Ozcan O, et al. Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma. Gene. 2015;567(1):81\u20136. https:\/\/doi.org\/10.1016\/j.gene.2015.04.065.","journal-title":"Gene"},{"issue":"9","key":"7038_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/ni.2073","volume":"12","author":"F Ma","year":"2011","unstructured":"Ma F, Xu S, Liu X, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-\u03b3. Nat Immunol. 2011;12(9):861\u20139. https:\/\/doi.org\/10.1038\/ni.2073.","journal-title":"Nat Immunol"},{"issue":"11","key":"7038_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2017.1356143","volume":"6","author":"A Ling","year":"2017","unstructured":"Ling A, L\u00f6fgren-Burstr\u00f6m A, Larsson P, et al. TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. Oncoimmunology. 2017;6(11):1\u201310. https:\/\/doi.org\/10.1080\/2162402X.2017.1356143.","journal-title":"Oncoimmunology"},{"key":"7038_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nri3896","volume":"15","author":"NR West","year":"2015","unstructured":"West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015;15:615\u201329. https:\/\/doi.org\/10.1038\/nri3896.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"7038_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10637-015-0216-8","volume":"33","author":"R Chakrabarty","year":"2015","unstructured":"Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M. The oncolytic virus, pelareorep, as a novel anticancer agent: a review. Investig New Drugs. 2015;33(3):761\u201374. https:\/\/doi.org\/10.1007\/s10637-015-0216-8.","journal-title":"Investig New Drugs"},{"key":"7038_CR22","doi-asserted-by":"publisher","unstructured":"Pentheroudakis G, Mavroeidis L, Papadopoulou K, et al. Angiogenic and antiangiogenic VEGFA splice variants in colorectal cancer: prospective retrospective cohort study in patients treated with irinotecan-based chemotherapy and bevacizumab. Clin Colorectal Cancer. 2019. https:\/\/doi.org\/10.1016\/j.clcc.2019.07.007.","DOI":"10.1016\/j.clcc.2019.07.007"},{"key":"7038_CR23","doi-asserted-by":"publisher","unstructured":"Bi H, Zhang Y, Wang S, et al. Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer. Oncol Lett. 2019:4176\u201384. https:\/\/doi.org\/10.3892\/ol.2019.10735.","DOI":"10.3892\/ol.2019.10735"},{"key":"7038_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jprot.2017.06.021","volume":"168","author":"Q Yang","year":"2017","unstructured":"Yang Q, Bavi P, Wang JY, Roehrl MH. Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases. J Proteome. 2017;168:53\u201365. https:\/\/doi.org\/10.1016\/j.jprot.2017.06.021.","journal-title":"J Proteome"},{"issue":"1","key":"7038_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-018-0076-8","volume":"3","author":"D Rao","year":"2019","unstructured":"Rao D, Parakrama R, Augustine T, Liu Q, Goel S, Maitra R. Immunotherapeutic advances in gastrointestinal malignancies. NPJ Precis Oncol. 2019;3(1):4. https:\/\/doi.org\/10.1038\/s41698-018-0076-8.","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"7038_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.physbeh.2017.03.040","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348. https:\/\/doi.org\/10.1016\/j.physbeh.2017.03.040.","journal-title":"Nat Rev Clin Oncol"},{"key":"7038_CR27","doi-asserted-by":"publisher","unstructured":"Eug\u00e8ne J, Jouand N, Ducoin K, et al. The inhibitory receptor CD94\/NKG2A on CD8+ tumor- infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE\/\u03b22m overexpression. Mod Pathol. 2019. https:\/\/doi.org\/10.1038\/s41379-019-0322-9.","DOI":"10.1038\/s41379-019-0322-9"},{"issue":"Nov","key":"7038_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02809","volume":"9","author":"L Agresta","year":"2018","unstructured":"Agresta L, Hoebe KHN, Janssen EM. The emerging role of CD244 signaling in immune cells of the tumor microenvironment. Front Immunol. 2018;9(Nov):1\u20139. https:\/\/doi.org\/10.3389\/fimmu.2018.02809.","journal-title":"Front Immunol"},{"issue":"May","key":"7038_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Gon\u00e7alves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9(May):1\u201319. https:\/\/doi.org\/10.3389\/fimmu.2018.00847.","journal-title":"Front Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07038-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07038-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07038-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:13:25Z","timestamp":1623957205000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07038-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7038"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07038-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-18123\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-18123\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-18123\/v3","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The entire study was performed in compliance with Institutional and Federal guidelines for clinical research. The study was approved by the ethics committee of Montefiore Medical Center\/Albert Einstein School of Medicine. All patient tissue and blood samples were drawn following written informed consent based on a local IRB approved consent form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no competitive\/financial interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"569"}}